Exousia Pro Creates New Subdivisions
Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has announced the creation of three new divisions under a newly formed subsidiary, Exousia Pro Holding Management, LLC (EPHM). The divisions include Exousia Ai, Exousia Health, and Exousia Wholesale, each structured for independent growth and potential future spin-offs.
The company plans to file two new patents in September 2025 and is developing new products for a market currently valued at $8.7 billion, expected to reach $18.5 billion in the next decade. Exousia Health is preparing to enter a partnership giving access to 200,000 active patients for marketing subscription-based health products.
Exousia Pro (OTCPINK:MAJI), una biotech in fase clinica, ha annunciato la creazione di tre nuove divisioni nell'ambito della nuova controllata Exousia Pro Holding Management, LLC (EPHM). Le divisioni, denominate Exousia Ai, Exousia Health ed Exousia Wholesale, sono strutturate per crescere in modo indipendente e potrebbero essere scorporate in futuro.
La società intende depositare due nuovi brevetti a settembre 2025 e sta sviluppando prodotti per un mercato attualmente valutato 8,7 miliardi di dollari, con una proiezione di 18,5 miliardi di dollari nel prossimo decennio. Exousia Health si sta preparando a una partnership che consentirà l'accesso a 200.000 pazienti attivi per la commercializzazione di prodotti sanitari in abbonamento.
Exousia Pro (OTCPINK:MAJI), una empresa biotecnológica en fase clínica, ha anunciado la creación de tres nuevas divisiones dentro de su subsidiaria recientemente formada, Exousia Pro Holding Management, LLC (EPHM). Las divisiones —Exousia Ai, Exousia Health y Exousia Wholesale— están diseñadas para crecer de forma independiente y podrían escindirse en el futuro.
La compañía planea presentar dos nuevas patentes en septiembre de 2025 y está desarrollando productos para un mercado valorado actualmente en 8.700 millones de dólares, con previsiones de alcanzar 18.500 millones de dólares en la próxima década. Exousia Health se está preparando para una asociación que dará acceso a 200.000 pacientes activos para comercializar productos sanitarios por suscripción.
Exousia Pro (OTCPINK:MAJI), 임상 단계의 바이오텍 기업이 새로 설립한 자회사 Exousia Pro Holding Management, LLC (EPHM) 산하에 세 개의 신규 사업부를 신설했다고 발표했습니다. 신설 사업부는 Exousia Ai, Exousia Health, Exousia Wholesale로, 각각 독립적 성장을 목표로 하며 향후 분사 가능성을 염두에 두고 구조화되어 있습니다.
회사는 2025년 9월에 두 건의 신규 특허를 출원할 계획이며, 현재 87억 달러 규모로 추정되는 시장을 대상으로 신제품을 개발 중입니다. 이 시장은 향후 10년 내에 185억 달러에 이를 것으로 예상됩니다. Exousia Health는 구독 기반 건강관리 제품을 마케팅하기 위해 20만 명의 활성 환자에 접근할 수 있는 파트너십을 준비 중입니다.
Exousia Pro (OTCPINK:MAJI), une société de biotechnologie en phase clinique, a annoncé la création de trois nouvelles divisions au sein de sa filiale nouvellement formée, Exousia Pro Holding Management, LLC (EPHM). Les divisions Exousia Ai, Exousia Health et Exousia Wholesale sont structurées pour croître de manière autonome et pourraient faire l'objet de futures scissions.
La société prévoit de déposer deux nouveaux brevets en septembre 2025 et développe de nouveaux produits pour un marché actuellement évalué à 8,7 milliards de dollars, qui devrait atteindre 18,5 milliards de dollars au cours de la prochaine décennie. Exousia Health se prépare à un partenariat offrant l'accès à 200 000 patients actifs pour la commercialisation de produits de santé par abonnement.
Exousia Pro (OTCPINK:MAJI), ein Biotech-Unternehmen in klinischer Phase, hat die Gründung von drei neuen Divisionen unter der neu gegründeten Tochtergesellschaft Exousia Pro Holding Management, LLC (EPHM) angekündigt. Die Divisionen Exousia Ai, Exousia Health und Exousia Wholesale sind so strukturiert, dass sie unabhängig wachsen und künftig ausgegründet werden können.
Das Unternehmen plant, im September 2025 zwei neue Patente anzumelden und entwickelt Produkte für einen Markt, der derzeit mit 8,7 Milliarden Dollar bewertet ist und in den nächsten zehn Jahren voraussichtlich 18,5 Milliarden Dollar erreichen wird. Exousia Health bereitet eine Partnerschaft vor, die Zugang zu 200.000 aktiven Patienten für die Vermarktung abonnementsbasierter Gesundheitsprodukte bieten wird.
- Creation of three specialized divisions with independent financial infrastructure and PCAOB auditing
- Access to 200,000 active patients through upcoming partnership
- Two new patent applications planned for September 2025
- Target market valued at $8.7 billion with projected growth to $18.5 billion
- Structure allows potential spin-offs to higher exchanges
- Still in clinical stage with no current revenue
- Heavy dependence on future patent approvals and partnerships
- Operating in highly competitive biotech sector
Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter.
The market for our new products is currently valued at
ORLANDO, FLORIDA / ACCESS Newswire / September 3, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, has filed with the State of Florida a new subsidiary to act as our operations holding company, Exousia Pro Holding Management, LLC ("EPHM"), for our three newly created divisions.
EPHM shall own
During September 2025, EPHM is expected to file for two new patents: one for use by Exousia Health and another for Exousia Wholesale. Further, we plan to file for several trademarks for products that our company has developed. In the near future, Exousia Health is expected to enter into a partnership that will provide us with access to approximately 200,000 active patients, enabling us to effectively market our products. These patients are currently spending thousands of dollars per month on their health regimens. By incorporating two of our patented and trademarked products, we can provide patients with an enhanced monthly subscription. These innovative additions are designed to complement their existing health regimens, improving their overall well-being.
Matt Dwyer, our President, stated, "Exousia Pro has outlined a plan we have developed that allows each segment of the Company to flourish and, if warranted, be spun off and listed on a higher exchange. Over the past few months, the team has been actively working on new products that we can bring to market with low overhead, allowing us to generate revenue as we continue to build other segments of the Company. Exousia Ai will always be our main division; the other divisions will allow us to keep our focus, yet develop shareholder value well beyond Glioblastoma."
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the three new divisions created by Exousia Pro (MAJI)?
What is the market potential for Exousia Pro's (MAJI) new products?
How many patients will Exousia Pro (MAJI) have access to through their new partnership?
What are Exousia Pro's (MAJI) patent plans for September 2025?
What is the purpose of Exousia Pro's (MAJI) new corporate structure?
